Editas Medicine (EDIT) Cash from Financing Activities (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Cash from Financing Activities of $17.2 million for Q3 2025, up 131.64% quarter-over-quarter from $7.4 million in Q2 2025.
Editas Medicine (EDIT) Cash from Financing Activities (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Cash from Financing Activities for 11 consecutive years, with $17.2 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Financing Activities changed N/A year-over-year to $17.2 million; the TTM figure through Sep 2025 stood at $78.7 million (up 7551.46% YoY), while the FY2024 annual figure was $56.0 million, down 52.54% from the prior year.
- Cash from Financing Activities rose to $17.2 million in Q3 2025 per EDIT's latest filing, from $7.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $261.5 million in Q1 2021 and bottomed at -$1.4 million in Q1 2025.
- Historically, Cash from Financing Activities has averaged $30.0 million across 5 years, with a median of $838000.0 in 2021.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 31923.16% — and 2025, when it tumbled 848.44%.
- Editas Medicine's Cash from Financing Activities stood at $1.1 million in 2021, then tumbled by 41.44% to $619000.0 in 2022, then decreased by 16.96% to $514000.0 in 2023, then surged by 10700.19% to $55.5 million in 2024, then slumped by 69.07% to $17.2 million in 2025.
- Business Quant data shows EDIT's Cash from Financing Activities at $17.2 million in Q3 2025, $7.4 million in Q2 2025, and -$1.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 17.17 Mn |
| Sep 30, 2025 | 17.17 Mn |
| Jun 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | 7.41 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Dec 31, 2024 | 55.51 Mn |
| Dec 31, 2024 | 55.51 Mn |
| Jun 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 322,000.00 |
| Mar 31, 2024 | 192,000.00 |
| Mar 31, 2024 | 192,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Jun 30, 2023 | 117.53 Mn |
| Jun 30, 2023 | 117.53 Mn |
| Dec 31, 2022 | 619,000.00 |
| Dec 31, 2022 | 619,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Sep 30, 2022 | 80,000.00 |